CYP2C19

CYP2C19 (cytochrome P450 2C19) is a liver enzyme responsible for breaking down a wide range of drugs, including certain benzodiazepines, antidepressants, and proton-pump inhibitors. It belongs to the cytochrome P450 superfamily — a set of enzymes that carry out most of the body's phase I drug metabolism, chemically transforming compounds into forms the kidneys can excrete.

What makes CYP2C19 distinctive is the degree of genetic variation in the gene that encodes it. Around two to three percent of Europeans and Africans, and up to fifteen to twenty percent of East Asians, carry loss-of-function variants that make them poor metabolizers — meaning the enzyme works poorly or not at all. At the other end, some individuals carry extra gene copies, making them ultrarapid metabolizers who clear substrates unusually fast. Both extremes produce real differences in how a drug behaves at a standard dose.

How it works · its role

CYP2C19 sits in the smooth endoplasmic reticulum of liver cells and, to a lesser degree, in the gut wall. When a drug reaches the liver, the enzyme uses an oxidation reaction — typically adding a hydroxyl group — to restructure the molecule, usually making it more water-soluble and pharmacologically inactive. Occasionally this process activates a prodrug rather than inactivating it.

Poor metabolizers accumulate higher blood levels of CYP2C19 substrates because clearance is slow; a standard dose behaves as though it were larger. Ultrarapid metabolizers do the opposite — the drug is cleared so quickly that a standard dose may produce little effect. Most people fall between these poles, in "normal" (extensive) or intermediate metabolizer categories.

Relevance to substances & effects

Several psychoactive and psychoactive-adjacent drug classes run through CYP2C19. Diazepam is partly cleared by this enzyme, so poor metabolizers may experience more prolonged sedation at a given dose than an average metabolizer would.

Among antidepressants, citalopram and escitalopram — SSRIs prescribed for depression and anxiety — depend substantially on CYP2C19 for clearance. Poor metabolizers can accumulate higher plasma concentrations, raising the risk of dose-dependent adverse effects. Fluvoxamine, another SSRI, works the other way: it is a potent inhibitor of CYP2C19 rather than a substrate, and adding it to a CYP2C19-dependent drug can sharply raise that drug's exposure.

Clopidogrel illustrates a third pattern: it is a prodrug that CYP2C19 must activate. Poor metabolizers receive substantially less antiplatelet benefit from it — a finding that has driven clinical guidance on genotype-aware prescribing.

These examples show why CYP2C19 appears as a metabolic flag across this encyclopedia's interaction profiles. Two drugs may each be unremarkable at standard doses, but if one inhibits CYP2C19 while the other depends on it for clearance, the combination can push the second drug to unexpectedly high levels. Actual interaction severities are documented on the interaction layer, where each severity is tied to its source data.